Interest in Tau immunotherapy in the Alzheimer’s disease (AD) field has increased due to clinical observations that tau pathology has a great impact on clinical progression1 and that spatial progression of tau pathology can be observed both in preclinical models2 and in the human brain3. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.